カルノシン酸 (Synonyms: Carnosic acid)

Name: Carnosic acid
Brand: MedChemExpress
SKU: HY-N0644
Rating: 5.0 (8 reviews)

製品番号: HY-N0644 純度: 98.08%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Carnosic acid is an orally active lipid absorption inhibitor. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 3650-09-7

容量	価格（税別）	在庫状況	数量
5 mg	$32	在庫あり	Estimated Time of Arrival: December 31
10 mg	$50	在庫あり	Estimated Time of Arrival: December 31
25 mg	$100	在庫あり	Estimated Time of Arrival: December 31
50 mg	$150	在庫あり	Estimated Time of Arrival: December 31
100 mg	$210	在庫あり	Estimated Time of Arrival: December 31
500 mg	$525	在庫あり	Estimated Time of Arrival: December 31
1 g		お問い合わせ
5 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

Other Forms of Carnosic acid:

Carnosic acid (Standard) 在庫あり

顧客検証

Cell Proliferation/Viability Assay

Cell Imaging/Staining

Flow Cytometry

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]; CCK-8 was used to assess the viability of A/R-induced H9c2 cells treated with different concentrations of Carnosic acid (CA) (1.25–40 μM; 48 h). The cell viability of H9c2 cells treated by anoxic/reoxygenation (A/R) was reversed after CA pretreatment at different concentrations.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]; The apoptotic rate was measured using Annexin V-FITC/PI detected by flow cytometry. H9c2 cells in the CA + A/R group were treated with 10 μM CA for 48 h H9c2 cells in the er-1 + A/R group were pretreated with 10 μM Fer-1 for 2 h. CA, Carnosic acid; A/R, anoxic/reoxygenation; Fer-1, ferrostatin-1.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]; Western blots were used to analyze the expression of ferroptosis-related proteins and Mfn2 in A/R-induced cells after Carnosic acid (CA) or Fer-1 pretreatment. H9c2 cells in the CA + A/R group were treated with 10 μM CA for 48 h; H9c2 cells in the Fer-1 + A/R group were pretreated with 10 μM Fer-1 for 2 h. The protein level of PTGS2 was higher, and that of GPX4 was lower in the A/R group than in the control group. However, pretreatment with CA and Fer-1 prevented these changes.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]; DCFH-DA-stained images for the detection of ROS (magnification, x400; scale bar, 20 μm). H9c2 cells in the CA + A/R group were treated with 10 μM CA for 48 h H9c2 cells in the Fer-1 + A/R group were pretreated with 10 μM Fer-1 for 2 h. CA, Carnosic acid; A/R, anoxic/reoxygenation; Fer-1, ferrpstatin-1.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2024 Apr 24;16(9):1257.; Carnosic acid (CA) dose-dependently Inhibits prostate cancer cell survival. PC-3 prostate cancer cells were treated without (Control) or with the indicated concentrations of Carnosic acid (CA) for 7 days followed by staining with methylene blue and colony counting.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2024 Apr 24;16(9):1257.; Carnosic acid (CA, 70 μM) inhibited Akt. PC-3 cells were treated without (Control) or with the indicated concentrations of CA or DTX for 24 or 48 h followed by whole cell lysate preparation and total protein yield assessment. Lysates (20 µg of protein) were resolved by SDS-PAGE and immunoblotted with specific antibodies against total or phosphorylated Akt (Ser473) or β-actin.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Feb 6;25(4):1950. [Abstract]; Carnosic acid (CA) caused concentration- and time-dependent inhibition of H1299 cell proliferation with an IC₅₀ of 47.3 µM and 27.1 µM for 24 h and 48 h, respectively.

: Carnosic acid purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Feb 6;25(4):1950. [Abstract]; Carnosic acid (CA) induced apoptosis of H1299 NSCLC cells. H1299 cells were treated for 24 h with 5 nM paclitaxel (PTX), 25 µM CA, or 50 µM CA, and nuclear morphology was assessed qualitatively using Hoechst 33342 and a BioTek Cytation 5 plate reader. CA-treated cells had noticeably smaller nuclei, which was consistent with the nuclear condensation that occurred during apoptosis.

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5 3 Compound: 8	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
A549	IC₅₀	5 3 Compound: 8	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
A549	IC₅₀	5 3 Compound: 8	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
AGS	IC₅₀	89.8 3 Compound: 1	Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
AGS	IC₅₀	89.8 3 Compound: 1	Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
AGS	IC₅₀	89.8 3 Compound: 1	Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
Hepatocyte	EC₅₀	94.8 3 Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	94.8 3 Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	95.7 3 Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	95.7 3 Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
HepG2	IC₅₀	41.3 3 Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
HepG2	IC₅₀	41.3 3 Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
HepG2	IC₅₀	41.3 3 Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
MIA PaCa-2	EC₅₀	5.5 3 Compound: CA	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
MIA PaCa-2	EC₅₀	5.5 3 Compound: CA	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
MRC5	IC₅₀	21.8 3 Compound: 1	Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
MRC5	IC₅₀	21.8 3 Compound: 1	Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
Hepatocyte	EC₅₀	94.8 3 Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
PANC-1	EC₅₀	150 3 Compound: CA	Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
Hepatocyte	EC₅₀	95.7 3 Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
PANC-1	EC₅₀	150 3 Compound: CA	Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
MIA PaCa-2	EC₅₀	5.5 3 Compound: CA	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
MRC5	IC₅₀	21.8 3 Compound: 1	Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
PANC-1	EC₅₀	150 3 Compound: CA	Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]

体外実験

Carnosic acid, a phenolic diterpene, is enriched in the leaves of Lamiaceae plants, and is particularly high in dried leaves of Rosmarinus officinalis L. and Salvia officinalis. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity. It is widely reported that Carnosic acid has a therapeutic potential in different types of cancer, mostly based on in vitro experiments. Carnosic acid has also shown neuroprotective effects in experimental models of neurodegenerative diseases, mainly through activation of the antioxidant NRF2/ARE pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

332.43

分子式

C₂₀H₂₈O₄

CAS 番号

3650-09-7

Appearance

Solid

Color

White to light yellow

SMILES

OC([C@@]([C@@]1([H])CCC2=CC(C(C)C)=C3O)(CCCC1(C)C)C2=C3O)=O

Structure Classification

Initial Source

輸送条件

Shipping with dry ice.

保管条件

-80°C, stored under nitrogen

溶剤 & 溶解度

体外:

DMSO : 130 mg/mL (391.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0082 mL	15.0408 mL	30.0815 mL
5 mM	0.6016 mL	3.0082 mL	6.0163 mL
10 mM	0.3008 mL	1.5041 mL	3.0082 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (6.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.15%

Select Batch:

データシート (279 KB) SDS (393 KB)

COA (257 KB) HNMR (511 KB) LCMS (135 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Yesil-Celiktas O, et al. Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines. Plant Foods Hum Nutr. 2010 Jun;65(2):158-63. [Content Brief]

[2]. Kiyofumi Ninomiya, et al. Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1943-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0082 mL	15.0408 mL	30.0815 mL	75.2038 mL
	5 mM	0.6016 mL	3.0082 mL	6.0163 mL	15.0408 mL
	10 mM	0.3008 mL	1.5041 mL	3.0082 mL	7.5204 mL
	15 mM	0.2005 mL	1.0027 mL	2.0054 mL	5.0136 mL
	20 mM	0.1504 mL	0.7520 mL	1.5041 mL	3.7602 mL
	25 mM	0.1203 mL	0.6016 mL	1.2033 mL	3.0082 mL
	30 mM	0.1003 mL	0.5014 mL	1.0027 mL	2.5068 mL
	40 mM	0.0752 mL	0.3760 mL	0.7520 mL	1.8801 mL
	50 mM	0.0602 mL	0.3008 mL	0.6016 mL	1.5041 mL
	60 mM	0.0501 mL	0.2507 mL	0.5014 mL	1.2534 mL
	80 mM	0.0376 mL	0.1880 mL	0.3760 mL	0.9400 mL
	100 mM	0.0301 mL	0.1504 mL	0.3008 mL	0.7520 mL

Carnosic acid Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Carnosic acid3650-09-7ApoptosisBacterialInhibitorinhibitorinhibit

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #

お名前 *

メールアドレス *

電話番号 *

部門 *

組纖名 *

国或いは地域 *

備考

お名前
メール *

	Sorry, but the email address you supplied was invalid.

カルノシン酸 (Synonyms: Carnosic acid)

カスタマーレビュー

Other Forms of Carnosic acid:

カルノシン酸 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

カルノシン酸 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Carnosic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

カルノシン酸関連抗体

カルノシン酸関連抗体